Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
What Is Varithena®?
Varithena® (polidocanol injectable foam) is the first and only FDA–approved foam for the treatment of incompetent great saphenous veins (GSV), accessory saphenous veins, and visible varicosities of the GSV system above and below the knee. Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
What Should Patients Expect With Varithena®?
Varithena® is administered via a minimally invasive, nonsurgical procedure for the treatment of varicose veins that only requires an ultrasound machine and standard medical supplies. There is no requirement for tumescent anesthesia or sedation.
Patients undergoing treatment with Varithena® can return to many of their normal activities and work following the procedure, however there are certain restrictions. Patients should walk/mobilize the same day and daily for the next month with minimal restrictions. In addition, patients are required to wear compression stockings for 2 weeks and to avoid heavy exercise for 1 week and extended periods of inactivity for 1 month.
How Does Varithena® Work?
Varithena® is intended to act as follows: the foam displaces blood from the vein to be treated and scleroses the endothelium.